Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FH5N
|
|||
| Former ID |
DIB014185
|
|||
| Drug Name |
IW-6118
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Phase 2 | [1] | |
| Company |
Ironwood Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fatty acid amide hydrolase (FAAH) | Target Info | Modulator | [2] |
| BioCyc | Anandamide degradation | |||
| KEGG Pathway | Retrograde endocannabinoid signaling | |||
| Panther Pathway | Anandamide degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01107236) Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction. U.S. National Institutes of Health. | |||
| REF 2 | The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.